• Je něco špatně v tomto záznamu ?

TMPRSS2-ERG gene fusion in prostate cancer

A. Burdova, J. Bouchal, S. Tavandzis, Z. Kolar

. 2014 ; 158 (4) : 502-510. [pub] 20141205

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc17006095

Grantová podpora
NT13573 MZ0 CEP - Centrální evidence projektů

BACKGROUND: The TMPRSS2-ERG gene fusion is one of the most widely spread chromosomal rearrangements in carcinomas. Since its discovery, a number of studies have examined its diagnostic, prognostic and therapeutic implications for prostate cancer where suitable biomarkers are still lacking. The publication data are inconsistent. The aim of this review was to critically evaluate the current clinical impact of this gene fusion. METHODS: The PubMed online database was used to search relevant reviews and original articles. RESULTS: Although the TMPRSS2-ERG gene fusion appears to be a suitable diagnostic biomarker, the prognostic implications of this gene fusion are still unclear. Several new strategies for therapeutically targeting ETS fusions and their modulators have been identified and are currently being investigated. CONCLUSION: Due to the heterogeneity of prostate cancer, the combination of several biomarkers is necessary to accurately assess the presence of prostate cancer, predict its potential clinical outcome and decide on appropriate therapy (e.g. PARP inhibitors).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17006095
003      
CZ-PrNML
005      
20191025132750.0
007      
ta
008      
170210s2014 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2014.065 $2 doi
035    __
$a (PubMed)25485532
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Burdova, Alena $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic; Laboratory of Medical Genetics, AGEL Laboratories, AGEL Research and Training Institute, Novy Jicin
245    10
$a TMPRSS2-ERG gene fusion in prostate cancer / $c A. Burdova, J. Bouchal, S. Tavandzis, Z. Kolar
520    9_
$a BACKGROUND: The TMPRSS2-ERG gene fusion is one of the most widely spread chromosomal rearrangements in carcinomas. Since its discovery, a number of studies have examined its diagnostic, prognostic and therapeutic implications for prostate cancer where suitable biomarkers are still lacking. The publication data are inconsistent. The aim of this review was to critically evaluate the current clinical impact of this gene fusion. METHODS: The PubMed online database was used to search relevant reviews and original articles. RESULTS: Although the TMPRSS2-ERG gene fusion appears to be a suitable diagnostic biomarker, the prognostic implications of this gene fusion are still unclear. Several new strategies for therapeutically targeting ETS fusions and their modulators have been identified and are currently being investigated. CONCLUSION: Due to the heterogeneity of prostate cancer, the combination of several biomarkers is necessary to accurately assess the presence of prostate cancer, predict its potential clinical outcome and decide on appropriate therapy (e.g. PARP inhibitors).
650    _2
$a nádorové biomarkery $7 D014408
650    _2
$a fúze genů $x genetika $7 D050939
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a fúzní onkogenní proteiny $x genetika $7 D015514
650    _2
$a prognóza $7 D011379
650    _2
$a nádory prostaty $x diagnóza $x genetika $7 D011471
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Bouchal, Jan, $d 1973- $7 xx0034399 $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
700    1_
$a Tavandzis, Spiros. $7 xx0239521 $u Laboratory of Medical Genetics, AGEL Laboratories, AGEL Research and Training Institute, Novy Jicin
700    1_
$a Kolář, Zdeněk, $d 1953- $7 jn20000710256 $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 158, č. 4 (2014), s. 502-510
856    41
$u http://biomed.papers.upol.cz/ $y domovská stránka časopisu
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20170210 $b ABA008
991    __
$a 20191025133226 $b ABA008
999    __
$a ok $b bmc $g 1192282 $s 966742
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 158 $c 4 $d 502-510 $e 20141205 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
GRA    __
$a NT13573 $p MZ0
LZP    __
$b NLK118 $a Pubmed-20170210
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace